Jinzi Zheng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6056629/publications.pdf

Version: 2024-02-01

41 papers	1,186 citations	361045 20 h-index	377514 34 g-index
42 all docs	42 docs citations	42 times ranked	2028 citing authors

#	Article	IF	Citations
1	Assessment of a liposomal CT/optical contrast agent for image-guided head and neck surgery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 32, 102327.	1.7	4
2	An integrated augmented reality surgical navigation platform using multi-modality imaging for guidance. PLoS ONE, 2021, 16, e0250558.	1.1	13
3	Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia. Molecular Imaging and Biology, 2020, 22, 653-664.	1.3	1
4	Nanoparticle-based CT visualization of pulmonary vasculature for minimally-invasive thoracic surgery planning. PLoS ONE, 2019, 14, e0209501.	1.1	3
5	Perfluorocarbon nanodroplets can reoxygenate hypoxic tumors in vivo without carbogen breathing. Nanotheranostics, 2019, 3, 135-144.	2.7	29
6	Intraoperative Near-Infrared Fluorescence-Guided Peripheral Lung Tumor Localization in Rabbit Models. Annals of Thoracic Surgery, 2019, 107, 248-256.	0.7	7
7	Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. PLoS ONE, 2018, 13, e0196892.	1.1	5
8	Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis. Molecular Pharmaceutics, 2018, 15, 4132-4138.	2.3	16
9	Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. Theranostics, 2018, 8, 2300-2312.	4.6	47
10	Multi-Modal Imaging in a Mouse Model of Orthotopic Lung Cancer. PLoS ONE, 2016, 11, e0161991.	1.1	7
11	Rapid Detection of Necrosis in Breast Cancer with Desorption Electrospray Ionization Mass Spectrometry. Scientific Reports, 2016, 6, 35374.	1.6	57
12	Spatial Measurements of Perfusion, Interstitial Fluid Pressure and Liposomes Accumulation in Solid Tumors. Journal of Visualized Experiments, 2016, , .	0.2	6
13	Evaluation of PET Imaging Performance of the TSPO Radioligand [18F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation. Molecular Imaging and Biology, 2016, 18, 127-134.	1.3	12
14	Chapter 6. The Role of Imaging in Nanomedicine Development and Clinical Translation. RSC Drug Discovery Series, 2016, , 151-181.	0.2	0
15	Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance. Journal of Visualized Experiments, 2015, , e53055.	0.2	11
16	Longitudinal tumor hypoxia imaging with [18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity. EJNMMI Research, 2015, 5, 57.	1.1	6
17	Ambient Mass Spectrometry Imaging with Picosecond Infrared Laser Ablation Electrospray Ionization (PIR-LAESI). Analytical Chemistry, 2015, 87, 12071-12079.	3.2	49
18	Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). Molecular Cancer Therapeutics, 2015, 14, 2060-2071.	1.9	51

#	Article	IF	Citations
19	Whole-body organ-level and kidney micro-dosimetric evaluations of 64Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates. EJNMMI Research, 2015, 5, 24.	1.1	14
20	Contrast Agent Mass Spectrometry Imaging Reveals Tumor Heterogeneity. Analytical Chemistry, 2015, 87, 7683-7689.	3.2	31
21	A multimodal nano agent for image-guided cancer surgery. Biomaterials, 2015, 67, 160-168.	5.7	45
22	A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 155-165.	1.7	51
23	Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice. Journal of Controlled Release, 2014, 178, 69-78.	4.8	69
24	Nanotechnology for Multimodality Imaging: Applications in Disease Detection and Treatment Guidance. Frontiers in Nanobiomedical Research, 2014, , 145-193.	0.1	0
25	The Translocator Protein Radioligand ¹⁸F-DPA-714 Monitors Antitumor Effect of Erufosine in a Rat 9L Intracranial Glioma Model. Journal of Nuclear Medicine, 2013, 54, 2125-2131.	2.8	37
26	A Mathematical Model of the Enhanced Permeability and Retention Effect for Liposome Transport in Solid Tumors. PLoS ONE, 2013, 8, e81157.	1.1	66
27	Long Circulation and Tumor Accumulation. , 2013, , 543-571.		3
28	A Novel Minimally Invasive Technique to Create a Rabbit VX2 Lung Tumor Model for Nano-Sized Image Contrast and Interventional Studies. PLoS ONE, 2013, 8, e67355.	1.1	37
29	The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 811-823.	3.3	80
30	Differential Expression of the 18 kDa Translocator Protein (TSPO) by Neoplastic and Inflammatory Cells in Mouse Tumors of Breast Cancer. Molecular Pharmaceutics, 2011, 8, 823-832.	2.3	37
31	APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. Journal of Controlled Release, 2011, 154, 298-305.	4.8	76
32	Liposome contrast agent for CTâ€based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDGâ€PET and histology. Contrast Media and Molecular Imaging, 2010, 5, 147-154.	0.4	27
33	Targeting Focal Adhesion Kinase with Dominant-Negative FRNK or Hsp90 Inhibitor 17-DMAG Suppresses Tumor Growth and Metastasis of SiHa Cervical Xenografts. Cancer Research, 2009, 69, 4750-4759.	0.4	37
34	Quantitative CT Imaging of the Spatial and Temporal Distribution of Liposomes in a Rabbit Tumor Model. Molecular Pharmaceutics, 2009, 6, 571-580.	2.3	62
35	Quantitative CT Imaging of the Spatial and Temporal Distribution of Liposomes in a Rabbit Tumor Model. Molecular Pharmaceutics, 2009, 6, 1040-1040.	2.3	1
36	Improved CT and MR image registration with the introduction of a dual-modality contrast agent: performance assessment using quantitative and information theoretic methods. , 2008, , .		1

#	Article	IF	Citations
37	Nanosystems for Multimodality In vivo Imaging. Fundamental Biomedical Technologies, 2008, , 409-430.	0.2	1
38	Longitudinal vascular imaging using a novel nano-encapsulated CT and MR contrast agent. , 2007, , .		3
39	In Vivo Performance of a Liposomal Vascular Contrast Agent for CT and MR-Based Image Guidance Applications. Pharmaceutical Research, 2007, 24, 1193-1201.	1.7	103
40	Multimodal Contrast Agent for Combined Computed Tomography and Magnetic Resonance Imaging Applications. Investigative Radiology, 2006, 41, 339-348.	3.5	80
41	Nanoengineered multimodal contrast agent for medical image guidance. , 2005, , .		1